Justifying prenatal screening and genetic amniocentesis programs by cost-effectiveness analyses: A re-evaluation

Medical Decision Making

Volumn 16, Issue 1, 1996, Pages 45-50

  Ganiats, Theodore G ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abortion; Amniocentesis; Cost effectiveness analysis; Health policy

Indexed keywords

AMNIOCENTESIS; ARTICLE; COST EFFECTIVENESS ANALYSIS; GENETIC ANALYSIS; GENETIC DISORDER; HEALTH CARE POLICY; HUMAN; MEDICAL DECISION MAKING; PRENATAL DIAGNOSIS; PRENATAL DISORDER;

GENETICS AND REPRODUCTION;

ABORTION, EUGENIC; AMNIOCENTESIS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; ETHICS, MEDICAL; FEMALE; GENETIC SCREENING; HEALTH POLICY; HUMANS; PREGNANCY; SOCIAL VALUES;

EID: 0030048402     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X9601600112     Document Type: Article

References (61)

1. Weinstein M, Fineberg H Clinical Decision Analysis. Philadelphia: W B. Saunders, 1980
2. Bloom B, Hillman A, Fendrick A, Schwartz J. A reappraisal of hepatitis B virus vaccination strategies using cost - effectiveness analysis. Ann Intern Med. 1993;118:298-306.
3. Bush JF, Fanshel S, Chen M Analysis of a tuberculin testing program using a health status index. J Socio-Econ Plan Sci 1972;6:46-9.
4. Bush JW, Chen M, Patrick DL. Cost - effectiveness using a health status index: analysis of the New York State PKU Screening Program. Hospital Research and Educational Trust 1973,36.
5. Ganiats TG, Humphrey JB, Taras HL, Kaplan RM Routine neonatal circumcision: a cost - utility analysis Med Decis Making 1991,11:282-93.
6. Laurence K. Fetal malformations and abnormalities. Lancet. 1974;2(7886):939-42.
7. Twiss SBJ Examining the pros and cons of parental responsibility for genetic health. Hastings Center Rep 1974;4:9-11.
8. Komrower G The philosophy and practice of screening for inherited diseases. Pediatrics 1974;53:182-8.
9. Fudenberg H. Fiscal returns of biomedical research. J Invest Dermatol. 1973;61:321-9.
10. Danks D. Prospects for the prevention of genetic disease. Med J Aust 1973;1:573-7.
11. Stein Z, Susser M, Guterman A. Screening programme for prevention of Down's syndrome Lancet. 1973;1(798):305-10
12. Fletcher J. Prenatal diagnosis, selective abortion, and the ethics of withholding treatment from the defective newborn. Birth Defects Original Article Series. 1979,15:239-54.
13. Yeaworth K. Ethics. the agonizing decisions in mental retardation. Am J Nurs 1977;77:864-7
14. Layde PM, von Allmen SD, Oakley GPJ Maternal serum alpha-fetoprotein screening: a cost-benefit analysis. Am J Public Health 1979;69:566-73.
15. Selle H, Holmes D, Ingbar M. The growing demand for midtrimester amniocentesis: a systems approach to forecasting the need for facilities. Am J Public Health. 1979;69:574-80.
16. Wald N, Cuckle H, Boreham J, Brett R, Stirrat G Antenatal screening in Oxford for fetal neural tube defect. Br J Obstet Gynaecol. 1979;86:91-100.
17. Pauker SP, Pauker SG. The amniocentesis decision: an explicit guide for parents. Birth Defects Original Article Series. 1979;15:289-324
18. Read A Costs and benefits of serum alpha-fetoprotein screening [letter]. Br Med J. 1978;2(6154) 1787.
19. Chamberlain J. Human benefits and costs of a national screening programme for neural-tube defects. Lancet. 1978,2(8103). 1293-6.
20. Hagard S, Carter F, Milne R Screening for spina bifida cystica. A cost - benefit analysis. Br J Prev Soc Med. 1976,30:40-53
21. Findley S, Potter R, Findley T. Alternative strategies of fetal sex diagnoses and sex preselection Soc Biol 1984;31:120-39.
22. Andreano RL, McCollum DW. A benefit - cost analysis of amniocentesis. Soc Biol. 1983;30:347-73
23. Wible-Kant J, Beer A Antepartum Rh immune globulin. Clin Perinatol. 1983;10:343-55.
24. Sadovnick A, Baird P. A cost - benefit analysis of prenatal diagnosis for neural tube defects selectively offered to relatives of index case. Am J Med Genet. 1982;12:63-73
25. Bobrow M, Lindenbaum R, Seabright M, Gregson N. Karyotyping amniotic fluids from patients with high serum alpha-fetoprotein. Lancet. 1981,1(8220):606-7.
26. Cowchock S, Jackson L. Use of alpha-fetoprotein for diagnosis of neural tube and other anomalies. Clin Obstet Gynaecol. 1980;7:83-102.
27. Maternal serum alpha-fetoprotein screening for neural tube defects. Results of a consensus meeting. Prenat Diagn 1985,5:77-83
28. McCormack M Screening for genetic traits and diseases. Am Fam Physician. 1981;24:153-66.
29. Nolan-Haley J Amniocentesis and the apotheosis of human quality control J Leg Med. 1981;2:347-63.
30. Smith JD. Down's syndrome, amniocentesis. and abortion: prevention or elimination? Ment Retard 1981;19:8-11
31. Trotzig M The defective child and the actions for wrongful life and wrongful birth J Leg Med. 1980;2 85-111.
32. Boling R, Schipul AJ, Barnhill D, Chaney S, Beam T. Prevalence of neural tube defects in United States Army treatment facilities Milit Med. 1988;153:293-5
33. Campbell T. Maternal serum alpha-fetoprotein screening: benefits, risks, and costs J Fam Pract. 1987;25:461-7.
34. Bell J, Pearn J, Smith A Prenatal cytogenetic diagnosis. Amniotic cell culture versus chorionic villus sampling Med J Aust. 1987;146:27-9.
35. Gill M, Murday V, Slack J An economic appraisal of screening for Down's syndrome in pregnancy using maternal age and serum alpha fetoprotein concentration. Soc Sci Med 1987,24:725-31
36. Marchese C, Viora E, Campogrande M, Carbonara A. Cost - effectiveness ratio of chorionic villi biopsy for the prenatal diagnosis of chromosomal aberrations as compared with amniocentesis Ricerca in Clinica E in Laboratorio 1986;16:533-8.
37. Benoit J, Merrill S, Rundell C, Meeker C. Amniostat-FLM: An initial clinical trial with both vaginal pool and amniocentesis samples Am J Obstet Gynecol. 1986;154:65-8.
38. Bell J, Pearn J, Prenatal cytogenotic diagnosis: medical and social implications. Indications, acceptance by doctors and patients, impact and cost: a 10-year review. Med J Aust. 1985;143:76-9.
39. Bowman J Controversies in Rh prophylaxis. Who needs Rh immune globulin and when should it be given? Am J Obstet Gynecol. 1985,151:289-94.
40. Leschot N, Verjaal M, Treffers P. A critical analysis of 75 therapeutic abortions. Early Hum Dev. 1985;10:287-93.
41. Edel C, Edel M Economic costs of aneuploidy: some problems of measurement and conceptualization, Basic Life Sci. 1985;36:61-73.
42. Goldstein H. Studies of various aspects of Down syndrome in Denmark, and their use as an epidemiological basis for cost benefit analysis of genetic amniocentesis. Dan Med Bull. 1992;39:489-508.
43. Goldstein H, Philip J. A cost - benefit analysis of prenatal diagnosis by amniocentesis in Denmark. Clin Genet. 1990;37:241-63.
44. Feeny DH, Torrance GW. Incorporating utility-based quality-of-life assessment measures in clinical trials. Med Care. 1989;27(3 Suppl):S190-204.
45. Etzioni A. Issues of public policy in the USA raised by amniocentesis J Med Ethics. 1976;2.8-11.
46. Shackley P, McGuire A, Boyd PA, et al. An economic appraisal of alternative prenatal screening programmes for Down's syndrome. J Public Health Med. 1993;15:175-84.
47. Moatti JP, Le Gales C, Julian C, Lanoe JL, Ayme S. Cost - benefit analysis of amniocentesis in the prenatal diagnosis of chromosome abnormalities. Revue D Epidemiologie et de Sante Publique 1990;38:309-21
48. Henderson JB. Measuring the benefits of screening for open neural tube defects. J Epidemiol Community Health. 1982;36:214-9.
49. Modell B, Kuliev AM. Services for thalassaemia as a model for cost-benefit analysis of genetics services. J Inherit Metab Dis 1991;14:640-51.
50. United States. President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Screening and Counseling for Genetic Conditions - A Report on the Ethical, Social, and Legal Implications of Genetic Screening, Counseling, and Education Programs. Washington, DC: U.S.G.P.O., 1993.
51. Harris J. Wonderwoman and Superman - The Ethics of Human Biotechnology Oxford, England: Oxford University Press, 1992
52. Pueschel SM. Ethical considerations relating to prenatal diagnosis of fetuses with Down syndrome. Ment Retard 1991;29 185-90.
53. Roe K. Private troubles and public issues: providing abortion and competing definitions. Soc Sci Med 1989;29:1191-8.
54. Susser M. Induced abortion and health as a value. Am J Public Health 1992;82:1323-4.
55. Kaplan R, Anderson J, Ganiats T. The Quality of Well-being scale: rationale for a single quality of life index. In: Walker R, ed. Quality of Life Assessment: Key Issues in the 1990s. 2nd ed London, England: MTM Press, 1993, p 30
56. Botkin JR. Prenatal screening, professional standards and the limits of parental choice. Obstet Gynecol 1990;75:875-80.
57. Hilgers T, Horan DJ. Abortion and Social Justice. New York: Sheet and Ward, 1972, p 44
58. Sanders D, DeCato CM, Smolen W. Sweet Sorrow: The color-shading response in an adult cystic fibrosis population. J Pers Assess. 1984;48:476-7
59. Baird PA. Life tables for Down syndrome. Hum Genet. 1989,82:291-2.
60. Wertz DC, Rosenfield JM, Janes SR, Erbe RW. Attitudes toward abortion among parents of children with cystic fibrosis. Am J Public Health. 1991;81:992-6.
61. Weinstein M, Stason W. Hypertension - A Policy Perspective Cambridge, MA: Harvard University Press, 1976.